Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on LONZA GROUP AG-REG. We currently have 10 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
LONZA GROUP AG-REG
LONZA GROUP AG-REG
A huge move to close the year...Lonza acquires Capsugel
15 Dec 16
Lonza has confirmed it will acquire US Capsugel, a manufacturer of a wide range of dosage forms for the pharmaceutical and nutrition industries for US$5.5bn from KKR, which bought it in FY11 for US$2.36bn from Pfizer. The deal, if approved, should be closed in Q2 17, and Lonza will proceed with a capital increase of up to CHF3.3bn to finance it.
Updating our assumptions
17 Nov 16
After the group’s Capital Markets Day, held in Portsmouth, USA, at the end of October and discussions we had with the group’s IR team, we have updated our model, integrating, in particular, the newly-acquired Interhealth to our numbers and also revising the Pharma&Biotech segment prospects.
Q3 business overview: everything looks just fine!
27 Oct 16
Lonza released its Q3 « qualitative business overview » and held its investors day in the US. The Pharma&Biotech segment is said to enjoy continued strong performance in revenue and profitability while the Speciality Ingredients segment posts robust results thanks to portfolio management. The group upgraded its guidance for FY16 core EBIT growth, from a double-digit growth to « over 15% growth ».
H1 16 earnings: hats off !
20 Jul 16
Lonza reported H1 16 earnings which show a +6% increase in sales (+4.7% at CER) to CHF1,904m, a +14.3% increase in core EBITDA to CHF447m, +20% in core EBIT (CHF312m) and an 18.3% drop in net to CHF1,505m (vs CHF1,842m a year ago and CHF1,660m at year-end 2015). Operating cash flow is down some 12% to CHF264m. With these numbers the group raises its 2016 outlook, now calling for a double-digit increase in core EBIT (vs at least +5% previously) while management keeps its « long-term » target of an EBITDA « approaching CHF1bn » for FY18.
Q1 trading statement looks fine, even without numbers !
26 Apr 16
Lonza released its Q1 16 trading statement, which, as usual, does not include hard numbers. The business development in Q1 is said to be good in both the Speciality Indredients and Pharma & Biotech segments. On this basis, the group expects a double-digit core EBIT growth in H1, while the full-year guidance will be discussed with the H1 results on 20 July. Note, so far, the FY16 guidance (released in January with the FY15 results) points to a growth in sales and a core EBIT growth of at least 5%.
N+1 Singer - Small-cap quantitative research - Momentum screen refresh + 10 focus stocks
12 Jan 17
We have refreshed our momentum style screen for the first time since inception on 26 July 2016. As before, the screen selects the 25 stocks exhibiting the most extreme momentum characteristics, according to our measurement method. From these we have selected 10 to focus on. Since inception the screen has underperformed both the main small-cap and micro-cap indices against a background of generally rising momentum. We have noted a subset of the basket, where decelerating momentum at the time of measurement appears correlated with significant share price falls since selection. We shall monitor this factor with the new screen, albeit there are only two such stocks showing this pattern, namely Lamprell (not rated) and Gear4music (not rated).
N+1 Singer - Morning Song 12-01-2017
12 Jan 17
As anticipated, the second half has again been stronger than H1 and results will be broadly in line with expectations. In line with this, the order book has continued to grow and is at record levels. This confirms that significant progress has been made in the Group’s shift towards its Technology Products division which, as targeted, contributed c.60% of group revenue in FY16. The small acquisition of Cable Power also gives a complementary boost to the product range. It is also worth noting the significant reduction in net debt, £1.0m ahead of our forecast. We remain supportive of the Group’s strategy and continue to see a bright future as this transition towards a design led technology solutions business continues. We look forward to more detail in March at the final results.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - Morning Song 16-01-2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.